These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38375992)

  • 21. Human papillomavirus-associated cutaneous disease burden in human immunodeficiency virus (HIV)-positive patients: the role of human papillomavirus vaccination and a review of the literature.
    Bacik LC; Chung C
    Int J Dermatol; 2018 Jun; 57(6):627-634. PubMed ID: 29152727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer.
    Tjalma WA; Arbyn M; Paavonen J; van Waes TR; Bogers JJ
    Int J Gynecol Cancer; 2004; 14(5):751-61. PubMed ID: 15361181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study.
    Liu Y; Li Z; Yuan L; Liu F; Wu K; Xiao X; Zhu C
    J Infect Public Health; 2023 Jul; 16(7):989-995. PubMed ID: 37167646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
    Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
    Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
    Lehtinen M; Pimenoff VN; Nedjai B; Louvanto K; Verhoef L; Heideman DAM; El-Zein M; Widschwendter M; Dillner J
    Int J Cancer; 2023 Mar; 152(6):1060-1068. PubMed ID: 36093582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of human papillomavirus in the malignant transformation of cervix epithelial cells and the importance of vaccination against this virus.
    Ciesielska U; Nowińska K; Podhorska-Okołów M; Dziegiel P
    Adv Clin Exp Med; 2012; 21(2):235-44. PubMed ID: 23214288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
    Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
    Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
    Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot.
    Petrie K; Wells A; Eckert LO
    Obstet Gynecol Clin North Am; 2023 Jun; 50(2):339-348. PubMed ID: 37149314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV vaccination: the beginning of the end of cervical cancer? - A Review.
    Lepique AP; Rabachini T; Villa LL
    Mem Inst Oswaldo Cruz; 2009 Feb; 104(1):1-10. PubMed ID: 19274369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
    Nartey Y; Amo-Antwi K; Hill PC; Dassah ET; Asmah RH; Nyarko KM; Agambire R; Konney TO; Yarney J; Damale N; Cox B
    PLoS One; 2023; 18(1):e0280437. PubMed ID: 36656844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathogenesis of cervical cancer.
    Ibeanu OA
    Cancer Biol Ther; 2011 Feb; 11(3):295-306. PubMed ID: 21239888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials of human papillomavirus vaccines and beyond.
    Lehtinen M; Dillner J
    Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
    Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
    Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic HPV vaccines.
    Hancock G; Hellner K; Dorrell L
    Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():59-72. PubMed ID: 29108943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the proportion of cervical cancers attributable to HPV.
    Brotherton JM; Budd AC; Saville M
    Med J Aust; 2020 Feb; 212(2):63-64.e1. PubMed ID: 31909481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.